EUVIMEDEUVIMED entdecken
Crossref

Targeting ferroptosis with chenodeoxycholic acid improves residual cardiac dysfunction after surgical ventricular reconstruction

Qiuhan Wang, Lu Chen, Bingxiang Shen, Junyu Yan, Xiaokang Fu, Ao Cheng, Dan Han, Jianping Bin, Yulin Liao iD, Siyuan Ma

British Journal of Pharmacology · 09.07.2026

DOI: 10.1111/bph.70542 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, online erschienen am 09.07.2026. Verfasst von Qiuhan Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Guangdong Provincial Key Lab of Cardiac Function and Microcirculation, Nanfang Hospital, Southern Medical University, Guang…. Die Arbeit nennt 42 Literaturangaben. Gefördert von: National Key Research and Development Program of China, The Science and Technology Projects in Guangzhou, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Surgical ventricular reconstruction (SVR) partially reverses left ventricular remodelling in postinfarction heart failure, yet residual cardiac dysfunction persists through unknown mechanisms. We investigated ferroptosis involvement in post‐SVR pathology and explored pharmacological interventions. Experimental Approach Myocardial infarction (MI) was induced in C57BL/6 mice followed by SVR at 4 weeks. Cardiac function was assessed by echocardiography and pressure–volume catheterization. Ferroptosis biomarkers were quantified. Connectivity Map analysis identified candidate compounds validated in Erastin‐challenged AC16 cardiomyocytes and SVR mouse models. Key Results Compared with MI group, SVR improved the left ventricular end‐diastolic volume index by 36.8% but showed persistent iron overload, glutathione depletion and elevated malondialdehyde. Transcriptomic analysis identified 90 ferroptosis‐related differentially expressed genes following SVR. Connectivity Map prioritized three ferroptosis inhibitors, and chenodeoxycholic acid (CDCA) exhibited superior efficacy. Farnesoid X receptor (FXR) knockdown in AC16 cardiomyocytes exacerbated erastin‐induced ferroptosis, while CDCA co‐treatment significantly reduced erastin‐induced ROS production, upregulated glutathione peroxidase 4 (GPX4) expression, and restored superoxide dismutase activity, rescued the ferroptotic phenotype and reversed associated molecular changes in FXR‐knockdown cells. In SVR‐treated mice, 3‐week CDCA administration (50 mg·kg −1 ·day −1 ) reduced myocardial iron deposition by 14.8%, improved left ventricular ejection fraction from 23.73% to 31.61% and restored GSH/GSSG ratio from 1.645 to 1.988. CDCA up‐regulated GPX4 expression by 1.573‐fold compared with the vehicle group. Conclusion and Implications SVR paradoxically exacerbates ferroptosis in residual myocardium through iron dysregulation and antioxidant depletion. CDCA, a primary bile acid activating FXR signalling, is a novel pharmacological strategy to mitigate post‐SVR ferroptosis and improve cardiac outcomes.

Schlagwörter

Stichwörter der Autor:innen

FXR receptorchenodeoxycholic acidferroptosisglutathione peroxidase 4surgical ventricular reconstruction

Autor:innen und Institutionen

  • Department of Cardiology, Guangdong Provincial Key Lab of Cardiac Function and Microcirculation, Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • Chongqing Hospital, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Chongqing, China.
  • Department of Cardiology, Peking University Third Hospital, Beijing, China.
  • Department of Cardiology, Fuwai Shenzhen Hospital, Chinese Academy of Medical Sciences, Shenzhen, China.
  • Cardiovascular Center, the Sixth Affiliated Hospital, School of Medicine, South China University of Technology, Foshan, China.
  • Medical Simulation Center, Nanfang Hospital, Southern Medical University, Guangzhou, China.

ORCID-Profile: Yulin Liao

Förderung

  • National Key Research and Development Program of China
  • The Science and Technology Projects in Guangzhou
  • National Natural Science Foundation of China
  • National Basic Research Program of China

Zitieren

APA

Wang, Q., Chen, L., Shen, B., Yan, J., Fu, X., Cheng, A., Han, D., Bin, J., Liao, Y., & Ma, S. (2026). Targeting ferroptosis with chenodeoxycholic acid improves residual cardiac dysfunction after surgical ventricular reconstruction. British Journal of Pharmacology. https://doi.org/10.1111/bph.70542

Vancouver

Wang Q, Chen L, Shen B, Yan J, Fu X, Cheng A, et al. Targeting ferroptosis with chenodeoxycholic acid improves residual cardiac dysfunction after surgical ventricular reconstruction. British Journal of Pharmacology. 2026. doi:10.1111/bph.70542

BibTeX
@article{Wang2026,
  author = {Wang, Qiuhan and Chen, Lu and Shen, Bingxiang and Yan, Junyu and Fu, Xiaokang and Cheng, Ao and Han, Dan and Bin, Jianping and Liao, Yulin and Ma, Siyuan},
  title = {Targeting ferroptosis with chenodeoxycholic acid improves residual cardiac dysfunction after surgical ventricular reconstruction},
  journal = {British Journal of Pharmacology},
  year = {2026},
  doi = {10.1111/bph.70542}
}
Kostenlos starten →